
Security Check Required




FacebookJoin or Log Into Facebook   Email or PhonePasswordForgot account?Log InDo you want to join Facebook?Sign UpSign UpSecurity CheckPlease enter the text belowCan't read the text above?Try another text or an audio captchaText in the box:What's this?Security CheckThis is a standard security test that we use to prevent spammers from creating fake accounts and spamming users.SubmitEnglish (US)EspañolFrançais (France)中文(简体)العربيةPortuguês (Brasil)Italiano한국어Deutschहिन्दी日本語MessengerFacebook LitePeoplePlacesGamesLocationsCelebritiesMarketplaceGroupsRecipesMomentsInstagramAboutCreate AdCreate PageDevelopersCareersPrivacyCookiesAd ChoicesTermsSettingsActivity Log Facebook © 2017













 





Microsoft personalized ad preferences




 













To opt out of personalized ads in this browser, your browser history must allow first-party and third-party cookies and you must have your browsing experience set to NOT delete browsing history on exit. Instructions for enabling cookies and configuring your browsing history may be available in your browsers settings, privacy, or help documentation.

















Sign in
















  Hold on… We’re sorry but this didn’t work.                  You can’t turn off personalized ads right now because your browser is currently blocking third-party cookies. We can help you fix this issue.                Let’s get started:  Depending on what browser you use, open Options or Settings.                  Make sure that third-party cookies are not blocked anymore. To find out how, search your browser’s Help.                                 Revisit http://choice.microsoft.com/opt-out, and then on the “Personalized ads in this browser” tile, click Off.                 ext74081 




  About Our Ads To create a more customized online experience, some of the ads you may receive on Microsoft websites and apps are tailored to your previous activities, searches and site visits. You're in control and here's where you can make the advertising choice that's right for you. ext74075 




  Where Can I Learn More about Advertising on Microsoft Websites and Apps? Microsoft partners with Oath, AppNexus and other third party service providers to help present customized content and display advertisements on MSN, Outlook.com and other websites and apps. Microsoft also delivers search ads to Bing and our search syndication partners. Learn more about Microsoft’s privacy practices here. You can learn more about interest-based ads from Oath and AppNexus in their privacy statements: Oath and AppNexus. What Choices Do I Have About Interest-Based Advertising? On this page, you can opt out of receiving interest based advertising from Microsoft. You can also opt out of receiving interest-based advertising from all self-regulatory members, including Microsoft, Oath, AppNexus and other third party ad networks, at the following sites:  In the US: Digital Advertising Alliance (DAA) In Europe: European Interactive Digital Advertising Alliance (EDAA) In Canada: Ad Choices: Digital Advertising Alliance of Canada (DAAC)  You can control interest-based advertising in Windows apps by turning off the advertising ID in Windows Settings.  More choices  Do you want personalized ads from other companies?  Questions? If you have a privacy question or a question for the Chief Privacy Officer of Microsoft, please contact us by using our web form. We will respond to questions within 30 days. ext74076 




       Personalized ads in this browser     OFF    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting for this web browser.  Learn more           If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.          ext74078 




       Personalized ads wherever I use my Microsoft account     OFF   Sign in to change...    Opt-out is currently unavailable, please try again later.  Control the "personalized ads" setting that applies when you are signed in on any computer or device with your Microsoft account, including Windows, Windows phone, Xbox and other devices.  Learn more                    If you want Microsoft to show ads that might be relevant to you, click On. To show “generic” ads, click Off.         If you choose “generic” ads and use a browser, your choice applies to everyone when using that browser as long as you do not clear your cookies.          ext74079 




       Personalized ads in Windows         In your Windows Settings, you can turn off personalized ads that appear in apps on this device. You’ll still see ads, but they won’t be personalized anymore.     If you have Windows 8.1:            Access the charms by touching or moving your pointer to the right edge of the screen.                 Click or tap Settings, and then click or tap Change PC Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have Windows 10:            Click or tap the Start button.                 Click or tap Settings.                 Click or tap Privacy, and then turn off Let apps use my advertising ID for experiences across apps.          If you have a Windows mobile device:            Go to Settings.                 Tap on Privacy.                 Tap on Advertising ID, and then turn off Let apps use my advertising ID for experiences across apps.                If you want to turn off personalized ads from Microsoft wherever you use your Microsoft account including apps on Windows, Windows Phone, Xbox and other devices, you can do so by selecting the Microsoft account option above.    ext74080 














Legal
Privacy & Cookies
© 2017 Microsoft














Adam Gridley - President & Chief Executive Officer at Histogenics Corp.



























































                      NEWS HOME
                    

Advertising
Board and Executive Moves
Energy
Health Care
Hedge Funds
M & A
Private Equity
Technology








            You have  
            
9 free profiles

              left this month   
			      

                Start Your Free Trial ➤
              








            Hey, we noticed you're a RelSci Pro subscriber! Would you like to view the page there?
            

                View on RelSci Pro ➤
              




























































































































Email







LinkedIn







Facebook







Google+







Tweet







Reddit





Permalink





Adam Gridley
President & Chief Executive Officer at Histogenics Corp.



Overview
In The News Relationships Paths
Education Career History Boards & Committees Public Holdings Transactions 


Adam Gridley
President & Chief Executive Officer at Histogenics Corp.



 Overview



Age



44
                                  (Born 1973)
                                              




Notable Companies


Histogenics Corp.




Board Seats



1





Number of Relationships



                This person is connected to 187 people.
              






 In The News
          See more




GlobeNewswire
July 26, 2017





                        Histogenics Corporation to Present at the 37th Annual Canaccord Genuity Growth Conference                    





GlobeNewswire
June 27, 2017





                        Histogenics Completes Enrollment for Phase 3 Clinical Trial of NeocartÂ® to Treat Knee Cartilage Damage                    





GlobeNewswire
June 5, 2017





                        Histogenics Corporation Announces the Appointment of Donald Haut, Ph.D. as Chief Business Officer                    





GlobeNewswire
May 16, 2017





                        Histogenics Corporation to Present at Upcoming Industry Conferences                    





GlobeNewswire
May 15, 2017





                        Histogenics Corporation Receives Innovation Award                    







See full news coverage and complete stories with RelSci Professional.

Create Your News Feed








See  More 






 Relationships
              See Details




Jonathan Lieber

Chief Financial Officer at Histogenics Corp.




Peter S. Greenleaf

Chairman & Chief Executive Officer at Sucampo Pharmaceuticals, Inc.





Garheng Kong, M.D., Ph.D.

Advisor at Sovereign's Capital




David N. Gill

President & Chief Financial Officer at EndoChoice, Inc.





John H. Johnson

Former Chief Executive Officer at ImClone Systems, Inc.




Kevin Ratkin

Partner at HighCape Partners Management LLC





Josh Baltzell

Venture Partner at SightLine Partners LLC




Michael Lewis

Non-Executive Chairman, Board of Directors at The Foschini Group Ltd.





Shuichi Mizuno

Founder at Histogenics Corp.




Steve Basta

Chief Executive Officer & Director at Menlo Therapeutics, Inc.







See 177 more listings with RelSci Professional.

Start My Free Trial ➤








See 177 More 


 


 Paths to Adam Gridley



            Adam Gridley          




 You



 Connections via Relationship Science



 Adam Gridley






Sync your contacts to see how you can connect with Adam Gridley.

Start My Free Trial ➤








See  More 


 


 Educational Background



B.S. 


University of Denver

                  The University of Denver was founded in 1864 — just a few years after the city of Denver itself was founded. The University's 125-acre campus, a few miles south of downtown Denver, is home to more than 11,500 students hailing from all regions of the United States and 83 other countries. The University offers more than 100 undergraduate programs of study and more than 120 graduate and professional programs.                




MBA 


University of Denver - Daniels College of Business

                  Daniels College of Business, originally called the School of Commerce, Accounts and Finance, is established by the University of Denver, founded in 1864 and the oldest private university in the Rocky Mountain region. Daniels is among the first business colleges in the U.S.—a select group that includes Wharton, Chicago, Berkeley, Dartmouth, Northwestern, Pittsburg and Harvard.                





 Career History



President & Chief Executive Officer

                                    2014 - Current                


Histogenics Corp.


                  Histogenics Corp. engages in the development, marketing, and commercialization of musculoskeletal medicine. Its regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives, and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. The company was founded on June 28, 2000 and is headquartered in Waltham, MA.                




Senior Vice President-Technical Operations

                                    2012 - 2014                


Merz North America, Inc.


                  Merz North America, Inc. operates as an specialty healthcare company. It offers treatment solutions for aesthetics, dermatology and neurosciences. The company was founded in 1908 and is headquartered in Raleigh, NC.                




Senior Vice President-Corporate Development

                                    2008 - Prior                


BioForm Medical, Inc.


                  BioForm Medical, Inc. is a medical aesthetics company focused on developing and commercializing products that are used by physicians to enhance a patient's appearance. Their core product is Radiesse dermal filler, an injectable dermal filler designed to provide aesthetic improvement for patients. The company also offers Radiesse Voice and Radiesse Voice Gel for vocal fold insufficiency and Coaptite as a treatment for women who have stress urinary incontinence. BioForm Medical was founded in 1999 and is headquartered in San Mateo, CA.                




Director, Market Development

                                    2003 - 2014                


Merz Aesthetics, Inc.


                  Merz Aesthetics, part of Merz GmbH & Co. KGaA, is a company headquartered in the United States that develops technology for soft and hard tissue augmentation.                




Director, Business Development

                                    1996 - 2003                


Gliatech, Inc.


                  Gliatech, Inc. engages in the discovery and development of bio surgery and pharmaceutical products. The company was founded on August 12, 1987 and is headquartered in Cleveland, OH.                





 Boards & Committees



Corporate Boards ▾




Member, Board of Directors

                    2014 - Current                  


Histogenics Corp.

                    Histogenics Corp. engages in the development, marketing, and commercialization of musculoskeletal medicine. Its regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives, and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. The company was founded on June 28, 2000 and is headquartered in Waltham, MA.                  





 Public Holdings






Restricted data only for RelSci Professional users.

Start My Free Trial ➤








See  More 


 


 Transactions



 Details Hidden



                  Histogenics Corp. raised money in a private placement transaction                                  





 Other Affiliations




              Adam Gridley is affiliated with
                            Histogenics Corp., Merz North America, Inc., BioForm Medical, Inc., Merz Aesthetics, Inc., Gliatech, Inc., Histogenics Corp..
            





You've reached your 10 free profiles limit this month.
Upgrade to RelSci Pro today to enjoy unlimited article views and much more!

Start My Free Trial  ➤

Still not convinced? Check out our full listing of features here.












Are you a RelSci Pro Subscriber?

Login to RelSci Pro 
                        ➤


Not a Pro Subscriber? Log in here to manage your alerts









 Keep me signed in.
        

Login  ➤



        Forgot your Password?
    

























 I have read the LexisNexis terms & conditions




Sign Me Up  ➤






















Adam Gridley - Executive Bio, Compensation History, and Contacts - Equilar Atlas










 

















Log in | Sign up








x

 






As Featured In



















Adam Gridley
Dir., President and Chief Executive Officer at Histogenics


View Full Profile
Are you Adam Gridley? Claim your profile


 


Sign up for Equilar Atlas and view Adam Gridley's full profile. 
With Equilar Atlas, you can:



IDENTIFY corporate executives in Adam Gridley's  network and community.
												FOLLOW changes in Adam Gridley's employment and money-in-motion.
												CONNECT with Adam Gridley through your network of contacts.
												








Adam Gridley's Executive Work History


Current


Dir., President and Chief Executive Officer, 
Histogenics


Past
To view Adam Gridley's complete executive work history, sign up now
Education


														 B.S., 
															University of Denver


Age
44

 
 


Adam Gridley's Biography



Adam Gridley has served as our Chief Executive Officer and President since May 2014. Mr. Gridley previously served from October 2012 until May 2014 as Senior Vice President of Technical Operations at Merz North America, Inc., the North American business unit of Merz, Inc., a privately-held pharmaceuticals company. From September 2011 to October 2012, he was Senior Vice President, Operations & Product Development responsible for global research and development and manufacturing for Merz Aesthetics, Inc., a global business unit of Merz, Inc., and from July 2010 to September 2011, Mr. Gridley held the position of Senior Vice President, Product D ...
(Read More)

			Adam Gridley has served as our Chief Executive Officer and President since May 2014. Mr. Gridley previously served from October 2012 until May 2014 as Senior Vice President of Technical Operations at Merz North America, Inc., the North American business unit of Merz, Inc., a privately-held pharmaceuticals company. From September 2011 to October 2012, he was Senior Vice President, Operations & Product Development responsible for global research and development and manufacturing for Merz Aesthetics, Inc., a global business unit of Merz, Inc., and from July 2010 to September 2011, Mr. Gridley held the position of Senior Vice President, Product Development at Merz. From September 2008 to July 2010, Mr. Gridley was Senior Vice President, Corporate Development for BioForm Medical, Inc., a publicly-traded company acquired by Merz, Inc. Mr. Gridley holds a B.S. and an M.B.A from the University of Denver. We believe that Mr. Gridley's qualifications to serve as a director of our company include his extensive experience as an executive in the biotechnology industry and his prior service as a senior-level executive in both early stage and mature biotechnology companies.
		
Source: Histogenics on 04/28/2016
		
	

 






Sign up for Equilar Atlas and view Adam Gridley's full profile. 



												By accessing Equilar Atlas, you can view bios, network, salary and wealth events
												of industry-leading executives like Adam Gridley. More specifically, you'll be able to:
												

IDENTIFY corporate executives in Adam Gridley's  network and community.
												FOLLOW changes in Adam Gridley's employment and money-in-motion.
												CONNECT with Adam Gridley through your network of conections.
												




View Full Profile


 








Search for over 360,000 executive profiles.





/bio



													Example: Adam Gridley


















Adam Gridley's Connections (29)





Sign up now to view Adam Gridley's 29 connections »









Michael Lewis
Board Member, Histogenics









Jeffrey M. Nugent
Former Chairman of the Board and Chief Executive Officer, Sientra, Inc.









Kevin Rakin
Board Member, Histogenics









John H. Johnson
Board Member, Cempra, Inc.









Martin P. Sutter
Board Member, Abiomed









Derek A. Bertocci
Former Senior Vice President and Chief Financial Officer, Achaogen Inc









Garheng Kong
Board Member, Cempra, Inc.









Albert Cha
Board Member, KalVista Pharmaceuticals, Inc.









Peter S. Greenleaf
Chief Executive Officer and Chairman of the Board, Sucampo Pharmaceuticals, Inc.









Joshua J. Baltzell
Board Member, Entellus Medical, Inc.








Popular Profiles






														Sign up now to view more executive profiles »
														









Thomas J. Lynch
Executive Chairman, TE Connectivity Ltd.









John J. Kita
EVP and CFO, A. O. Smith









Carl G. Annessa
EVP and COO, Hornbeck Offshore Services, Inc.









Elon R. Musk
CEO and Chairman, Tesla









Michael C. Montgomery
Board Member, NMI Holdings, Inc.












×

Claim Your Profile Coming Soon
Interested in updating your biography and work history?
We're working on making it happen.
We'll email you when this feature is available.
Please enter valid email address.

Done


Thank you for your interest.
Ok






			Browse executive profiles:
			
				 A
			
				 B
			
				 C
			
				 D
			
				 E
			
				 F
			
				 G
			
				 H
			
				 I
			
				 J
			
				 K
			
				 L
			
				 M
			
				 N
			
				 O
			
				 P
			
				 Q
			
				 R
			
				 S
			
				 T
			
				 U
			
				 V
			
				 W
			
				 X
			
				 Y
			
				 Z



Equilar Homepage
Equilar Atlas
Equilar Insight
Equilar BoardEdge
Equilar Engage
Research Services
Knowledge Network
About Us
Login

ï¿½ 2017 Equilar All Rights Reserved. Privacy Policy
1100 Marshall Street, Redwood City, CA 94063 | Phone (650) 241-6600 | Fax (650) 701-0993
















Histogenics Announces Appointment of Adam Gridley to President and Chief Executive Officer 
























































Histogenics
Home  /  Press Releases  /  Histogenics Announces Appointment of Adam Gridley to President and Chief Executive OfficerNews
Press Releases

Histogenics Announces Appointment of Adam Gridley to President and Chief Executive Officer
May 12, 2014Pharmaceutical Executive Brings Extensive Product Development & Operational Expertise to Late-Stage Regenerative Medicine Company
Waltham, MA., May 12, 2014—Histogenics Corporation, a regenerative medicine company focused on developing and commercializing products in the musculoskeletal space, today announced the appointment of Adam Gridley to President and Chief Executive Officer and as a member of the Company’s Board of Directors. Mr. Gridley brings over 20 years of proven results in the medical device and pharmaceutical industries, with a combination of transactional and public markets experience as well as strong operational leadership and product development expertise. Mr. Gridley’s career has focused on strategic elements of corporate growth with a demonstrated and successful track record in strategic planning, manufacturing and R&D expansions, and corporate and technology integrations.
“Adam’s expertise in growing and leading biotech companies and R&D organizations will be critical as we progress our lead investigational product, NeoCart®, through a Phase 3 pivotal trial and ultimately toward potential approval and commercialization,” said the Company’s Chairman, Garheng Kong. “We believe that Adam’s proven leadership will facilitate our Company’s vision of leveraging our regenerative medicine platform to become an emerging leader in the musculoskeletal and orthopedics space,” continued Dr. Kong.
“I am excited to join Histogenics as the Company builds out its operational functions, technology platform and commercial infrastructure. I believe that Histogenics has a significant opportunity with its lead investigational product NeoCart®, which has the potential to become an innovative therapy alternative to the current standard of care for cartilage repair in the knee,” said Mr. Gridley. “The management team, investors and Board of Directors at Histogenics has done an outstanding job supporting NeoCart’s ongoing Phase 3 trial in the U.S., and I look forward to leading the company through this pivotal stage of strategic growth and development.”
Prior to joining Histogenics, Mr. Gridley most recently served as Senior Vice President, Technical Operations at Merz, a privately-held specialty healthcare company focused on the development and commercialization of products for aesthetics, dermatology and neurosciences, where he was a global site head responsible for manufacturing and quality operations, information technology and sourcing activities. Previously, Mr. Gridley was Senior Vice President of Corporate Development for BioForm Medical, Inc. a publically-traded company that was acquired by Merz in 2010. In this role Mr. Gridley was responsible for all business development, investor relations, strategic planning, product development activities and R&D functions for the organization. Prior to that Mr. Gridley held several key strategic leadership roles in the orthopedics space during his career including Director of Business Development and Investor Relations at Gliatech Inc. Mr. Gridley holds a Bachelor of Science and a Master of Business Administration from the University of Denver.
About Histogenics
Histogenics is a regenerative medicine company focused on developing and commercializing products in the musculoskeletal segment of the marketplace. Our regenerative medicine platform combines expertise in cell processing, scaffolding, tissue engineering, bioadhesives and growth factors to provide solutions that can be utilized individually or in concert to treat musculoskeletal-related conditions. Our first investigational product candidate, NeoCart®, leverages our platform to provide an innovative treatment in the orthopedic space, specifically cartilage damage in the knee. For more information on Histogenics, please visit the company website at www.histogenics.com.
About NeoCart
NeoCart®, our Phase 3 investigational product is an implant produced using a patient’s own cartilage cells. A Phase 1 clinical trial conducted in the United States demonstrated favorable preliminary results, which supported proceeding to a Phase 2 clinical trial. A Phase 2 clinical trial conducted in the United States comparing NeoCart® to the standard-of-care microfracture met its endpoints for safety and for improvement in pain and function. These results support the continued clinical development of NeoCart®. The two-year results of our Phase 2 clinical trial are publicly available (Crawford et al. J Bone Joint Surg Am. 2012;94:979-89). A Phase 3 clinical trial conducted in the United States comparing NeoCart® to the standard-of-care microfracture is currently in progress. Information about the study is available on http://www.NeoCartImplant.com and http://www.clinicaltrials.gov.
For additional inquiries, please email us at InvestorRelations@histogenics.com or call us at 781.547.7900.
Forward Looking Statement
This press release contains “forward looking statements” including statements about Histogenics’ future operating results, product development, potential alliances and intellectual property. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performances or achievements expressed or implied by the forward-looking statements.
 
830 Winter Street, 3rd Floor
Waltham, MA 02451
tel  781.547.7900
fax 781.547.4452
Email: InvestorRelations@histogenics.com

About Us
History
Management
Board of Directors
Scientific Advisory Board

Products & Platform
Products & Platform
NeoCart
Platform
About Regenerative Medicine
About Cartilage Repair

Investors
Investor Overview
Stock Information
Analysts
SEC Filings
Calendar of Events
Corporate Governance
Investor FAQs

News
Press Releases

Contact
Contact
Career Opportunities

 


 






Adam Gridley, President & CEO, Histogenics


























&timesJavascript is disabled
























Market Profiles



Login
Sign up



Login


Sign up








 







 Edit

Person













Adam Gridley



President & CEO
at
Histogenics


Location: Boston, MA





Add to My Lists

Claim

Share


Copy the following code on your page/blog


Suggested widget size



Mobile



Desktop









Adam Gridley



President & CEO
at
Histogenics


Location: Boston, MA




Add to My Lists

Claim

Share


Copy the following code on your page/blog


Suggested widget size



Mobile



Desktop




Mr. Adam Gridley has over 20 years of proven results in the medical device, biotechnology and pharmaceutical industries. Mr. Gridley’s career includes a combination of transactional and public markets experience as well as deep operational leadership and product development expertise. A strong interactive leader with significant experience in venture backed start-ups to large multinational pharmaceutical organizations, Mr. Gridley has led several products through the development and regulatory approval phases into commercialization by building and leading functionally diverse global teams. His strong experience in manufacturing and quality operations has also facilitated the worldwide regulatory approvals of several diverse manufacturing sites. Focused on raising growth capital and enhancing shareholder value, Mr. Gridley has managed venture capital and public offerings, and led many business development transactions with companies such as Boston Scientific, Wright Medical, Merck and Abgenix.
Before joining the Histogenics team, Mr. Gridley served in several senior roles of increasing responsibility at Merz, a privately-held specialty healthcare company focused on the development and commercialization of products for aesthetics, dermatology and neurosciences, where he was most recently Senior Vice President of Technical Operations. During his time at Merz, he served as the global site head responsible for a variety of functions, including R&D, Manufacturing, Quality Operations, Finance and IT. Previously, Mr. Gridley was Senior Vice President of Corporate Development for BioForm Medical, Inc. a publicly-traded company that was acquired by Merz in 2010. His responsibilities included all business development, investor relations, strategic planning, and R&D functions, and he was part of the leadership team who led the Company’s IPO and subsequent acquistion by Merz. Mr. Gridley has held several key strategic leadership roles in the orthopedics space during his career including Director of Business Development and Investor Relations at Gliatech Inc. Mr. Gridley holds a Bachelor of Science and a Master of Business Administration from the University of Denver.



6

Companies in Career





N/A

Related Markets





1

Colleagues





N/A

Related Investments








Alias
N/A



Industry
Medical Device, Equipment, Supplies Manufacturing




Tags
Business Development, Product Development, Investor Relations, Corporate Development, Strategy




Topics of Influence












N/A







N/A



























Careers








Achievements








Investments








Related People






 Edit
View all 



Adam GridleyCareer (9)






May-2014




Histogenics



President & CEO







Oct-2012 to May-2014




Merz North America



Senior Vice President, Technical Operations







Sep-2011 to Oct-2012




Merz Aesthetics



Senior Vice President, Operations & Product Development







Sep-2008 to Aug-2010




BioForm Medical



Senior Vice President, Corporate Development







Jul-2005 to Sep-2008




BioForm Medical



Vice President, Corporate Development







May-2004 to Jul-2005




BioForm Medical



Director of Corporate Development








Competencies










 Edit
View all 



Adam GridleyEducation (2)






1996



University of Denver









1994



University of Denver


Accounting









 Edit



Adam GridleyAchievements and Recognitions





Add Milestone


No milestones has been recorded for Adam Gridley






 Edit



Adam GridleyLinks





Add Link


No links has been recorded for Adam Gridley









Adam GridleyInvestments/Acquisitions





No investments has been recorded for Adam Gridley









Adam GridleyInvestments Representing Others





No investment reps has been recorded for Adam Gridley








Adam GridleyRelated People








Colleagues at Histogenics







Donald Haut

Chief Business Officer
Jun-2017












View all 



Adam GridleyRecommended Market Profiles (8)








Telemedicine

10,000 or More employees
19 companies








Social Media Marketing (ChiefMartec.com)

5,000 - 10,000 employees
111 companies








Big Data Universe List of Lists

10,000 or More employees
533 companies








Aggregated Marketing Technology

10,000 or More employees
2650 companies








Shared Economy Landscape (Jeremiah Owyang)

10,000 or More employees
267 companies








Inside Sales Landscape

10,000 or More employees
650 companies


















